secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-150768
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Clay B. Siegall resigns from Nurix Therapeutics board effective May 15, 2022
----------------------------------------------------------------------------

- Clay B. Siegall, Ph.D. resigned as Class II director and from Compensation Committee and Development Advisory Committee.
- Resignation effective May 15, 2022; no reason provided in the filing.
- No replacement named; board composition change disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522150768/0001193125-22-150768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522150768/d343186d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-150768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer